학술논문
Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop.
Document Type
article
Author
Shankar, Lalitha; Schöder, Heiko; Sharon, Elad; Wolchok, Jedd; Knopp, Michael; Wahl, Richard; Hall, Nathan; Yaffe, Martin; Towbin, Alexander; Farwell, Michael; Pryma, Daniel; Poussaint, Tina; Wright, Chadwick; Schwartz, Lawrence; Harisinghani, Mukesh; Mahmood, Umar; Wu, Anna; Leung, David; de Vries, Elisabeth; Tang, Ying; Beach, Gillian; Reeves, Steven; Ellingson, Benjamin
Source
The Lancet Oncology. 24(3)
Subject
Language
Abstract
As the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy clinical trials and clinical care. Additionally, investigational tools-including image analysis of standard-of-care scans (such as CT, magnetic resonance, and PET) with analytics, such as radiomics, functional magnetic resonance agents, and novel molecular-imaging PET agents-offer promising advancements for assessment of immunotherapy. To document current challenges and opportunities and identify next steps in immunotherapy diagnostic imaging, the National Cancer Institute Clinical Imaging Steering Committee convened a meeting with diverse representation among imaging experts and oncologists to generate a comprehensive review of the state of the field.